EXPO Exponent Inc.

Exponent Welcomes Dr. John Doyle as Group Vice President for Health Sciences

Exponent Welcomes Dr. John Doyle as Group Vice President for Health Sciences

MENLO PARK, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Exponent, Inc. (NASDAQ: EXPO) today announced the hiring of John Doyle, Dr.P.H., as Group Vice President, Health Sciences.

Dr. Doyle will lead the firm’s Health Sciences team, which applies deep interdisciplinary expertise to evaluate a broad range of environmental, occupational, medical, and public health issues that face the world.

“I am incredibly excited to welcome John to the Exponent team. He brings unique experience and perspective to Exponent, having founded, built and led premium healthcare research consultancies focused on the international biopharmaceutical sector, and also having served as a pharmaceutical industry executive focused on innovation,” said Dr. Catherine Corrigan, Chief Executive Officer and President. “John will be working closely with me, our Operating Committee, and other stakeholders to accelerate our growth in the life sciences sector, leveraging Exponent’s powerful multidisciplinary approach, data science expertise, and cross-industry reputation as a leader in the analysis of real-world product safety and performance,” continued Dr. Corrigan.

“Exponent has a long history of advising clients across industries as they leverage complex technologies and real-world evidence to improve human health and safety,” commented Dr. Doyle. “The firm is uniquely positioned with its world-class multidisciplinary expertise to advise the global pharmaceutical industry as it seeks to deliver breakthroughs beyond medicines, and to catalyze value-based healthcare centered on equitable and affordable access for patients. I look forward to engaging with the entire Exponent team, as we draw upon the intellectual rigor and data-driven analysis that are the hallmarks of the firm to deliver groundbreaking insights into human health.”

In addition to his deep strategic expertise, Dr. Doyle has authored over 200 abstracts and original research articles in a variety of therapeutic areas, with special concentration in oncology. He received Doctor and Master of Public Health degrees in Epidemiology from the Mailman School of Public Health at Columbia University, where he maintains an adjunct faculty position.

Exponent is an engineering and scientific consulting firm providing solutions to complex problems. Exponent’s inter-disciplinary organization of scientists, physicians, engineers, and business consultants draws from more than 90 technical disciplines to solve the most pressing and complicated challenges facing stakeholders today. The firm leverages over 50 years of experience in analyzing accidents and failures to advise clients as they innovate their technologically complex products and processes, ensure the safety and health of their users, and address the challenges of sustainability.

More information about Exponent can be found at .

Exponent may be reached at (888) 656-EXPO, , or . 



EN
17/05/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Exponent Inc.

 PRESS RELEASE

Exponent Increases Quarterly Dividend Payment from $0.30 to $0.31 per ...

Exponent Increases Quarterly Dividend Payment from $0.30 to $0.31 per Share for Q1 2026 MENLO PARK, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today announced that its Board of Directors has raised its quarterly cash dividend from $0.30 to $0.31 per share of common stock. The quarterly cash dividend of $0.31 per share of common stock is to be paid on March 20, 2026 to all common stockholders of record as of March 6, 2026. Exponent has paid, and expects to continue to pay, quarterly dividends each year in March, June, September, and December. Future declaratio...

 PRESS RELEASE

Exponent Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Exponent Reports Fourth Quarter and Fiscal Year 2025 Financial Results MENLO PARK, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the fourth quarter and fiscal year 2025 ended January 2, 2026. “We delivered a strong finish to 2025 reflecting the strength, diversification, and resilience of our portfolio,” stated Dr. Catherine Corrigan, President and Chief Executive Officer. “Growth in proactive engagements during the fourth quarter was driven by increased demand for user research services in the consumer electronics sector and...

 PRESS RELEASE

Exponent to Announce Fourth Quarter and Fiscal Year 2025 Results and H...

Exponent to Announce Fourth Quarter and Fiscal Year 2025 Results and Host Quarterly Conference Call on February 5, 2026 MENLO PARK, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO), today announced that it will report Fourth Quarter and fiscal year 2025 financial results for the period ended January 2, 2026 following the close of the market on Thursday, February 5, 2026. On that day, Dr. Catherine Corrigan, Chief Executive Officer and President, and Richard Schlenker, Executive Vice President and Chief Financial Officer, will host a conference call and webcast at 4:...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch